Tumor-tropic E. coli engineered as living T and NK cell engagers
Despite advances in immunotherapy, most solid tumors remain resistant to treatment. Immune cell engagers redirect cytotoxic lymphocytes against cancer, but limited tumor access, immunosuppressive microenvironments and systemic immune activation limit efficacy. Here we develop live immune modulating engagers (LIME), a modular platform where non-pathogenic, tumor-tropic Escherichia coli display…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
